Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
6.34M
-
Shares change
-
-2.82M
-
Total reported value, excl. options
-
$31.1M
-
Value change
-
-$13.8M
-
Number of buys
-
9
-
Number of sells
-
-11
-
Price
-
$4.90
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q1 2018
37 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q1 2018.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.34M shares
of 77.3M outstanding shares and own 8.2% of the company stock.
Largest 10 shareholders include Capital World Investors (1.43M shares), BVF INC/IL (721K shares), ORBIMED ADVISORS LLC (635K shares), Schonfeld Strategic Advisors LLC (385K shares), NEXTHERA CAPITAL LP (379K shares), DAFNA Capital Management LLC (378K shares), Invesco Private Capital, Inc. (342K shares), Point72 Asset Management, L.P. (307K shares), RENAISSANCE TECHNOLOGIES LLC (288K shares), and Tekla Capital Management LLC (280K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.